Katy Peters
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Katy Peters sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Katy Peters: 6 sponsored US clinical trials, none currently recruiting.
Katy Peters sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gliosarcoma, with 3 trials.
Upper-quartile sponsor footprint
Katy Peters sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
NCT01450826
Low Dose Naltrexone for Glioma Patients
NCT01303835
AMG 102 and Avastin for Recurrent Malignant Glioma
NCT01113398
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
NCT00979017
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
NCT00939991
Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
NCT00610571
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
Therapeutic Areas
How the Katy Peters early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 6 completed (100%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Gliosarcoma (3 trials), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Katy Peters: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Katy Peters sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Katy Peters page
6 registered trials is a research-attention snapshot, not an endorsement of Katy Peters or any single study.
- None of Katy Peters's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Gliosarcoma is the condition Katy Peters studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gliosarcoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Katy Peters pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.